Sevabertinib

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; sevabertinib for lung cancer, gemcitabine intravesical system and durvalumab for bladder cancer, azacitidine for leukemia, cemiplimab for skin cancer, and ropeginterferon alfa-2b for essential thrombocythemia.

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; sevabertinib for lung cancer, gemcitabine intravesical system and durvalumab for bladder cancer, azacitidine for leukemia, cemiplimab for skin cancer, and ropeginterferon alfa-2b for essential thrombocythemia.

Journal: International journal of clinical oncology

Published: September 06, 2026

New Treatment Strategies for Rare Genomic Alterations: EGFR Exon 20 Insertions and HER2-Deregulated Lung Cancer.

New Treatment Strategies for Rare Genomic Alterations: EGFR Exon 20 Insertions and HER2-Deregulated Lung Cancer.

Journal: Cancers

Published: July 06, 2026

HER2 Therapies in Non-Small Cell Lung Cancer (NSCLC).

HER2 Therapies in Non-Small Cell Lung Cancer (NSCLC).

Journal: International journal of molecular sciences

Published: April 08, 2026

Sevabertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer. Reply.

Sevabertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer. Reply.

Journal: The New England journal of medicine

Published: March 26, 2026

Sevabertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer.

Sevabertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer.

Journal: The New England journal of medicine

Published: March 26, 2026

Class-level DILI saturation and hERG-driven risk stratification among 2024-2025 FDA-approved kinase inhibitors: an in silico multi-platform safety analysis.

Class-level DILI saturation and hERG-driven risk stratification among 2024-2025 FDA-approved kinase inhibitors: an in silico multi-platform safety analysis.

Journal: Investigational new drugs

Published: March 16, 2026

Acquired ERBB2 Amplification and Overexpression as On-Target Resistance Mechanisms to Zongertinib With Subsequent Response to Trastuzumab-Deruxtecan: A Case Report.

Acquired ERBB2 Amplification and Overexpression as On-Target Resistance Mechanisms to Zongertinib With Subsequent Response to Trastuzumab-Deruxtecan: A Case Report.

Journal: JTO clinical and research reports

Published: March 09, 2026

Oral TKI sevabertinib approved for advanced HER2-mutant NSCLC.

Oral TKI sevabertinib approved for advanced HER2-mutant NSCLC.

Journal: Cancer

Published: March 04, 2026

HER2-ADC and HER2-TKI Overcomes HER2 Amplification as an Acquired Resistance to Zongertinib - A Case Report.

HER2-ADC and HER2-TKI Overcomes HER2 Amplification as an Acquired Resistance to Zongertinib - A Case Report.

Journal: Lung Cancer (Auckland, N.Z.)

Published: February 09, 2026

Sevabertinib (Hyrnuo) for NSCLC.

Sevabertinib (Hyrnuo) for NSCLC.

Journal: The Medical letter on drugs and therapeutics

Published: February 06, 2026

HER2 Alterations in Non-Small Cell Lung Cancer: Emerging Perspectives on the Therapeutic Landscape.

HER2 Alterations in Non-Small Cell Lung Cancer: Emerging Perspectives on the Therapeutic Landscape.

Journal: International journal of molecular sciences

Published: January 28, 2026

Recent advances in HER2-targeted inhibitors for cancer therapy.

Recent advances in HER2-targeted inhibitors for cancer therapy.

Journal: Pharmaceutical science advances

Published: January 16, 2026

Showing 1-12 of 20

Last Updated: 09/26/2026